A Case of Lung Abscess Caused by Double Immunosuppressive Therapy to Treat Ulcerative Colitis
Abstract
:1. Introduction
2. Presentation of Case Report
3. Discussion
4. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
Informed Consent
References
- Akiho, H.; Yokoyama, A.; Abe, S.; Nakazono, Y.; Murakami, M.; Otsuka, Y.; Fukawa, K.; Esaki, M.; Niina, Y.; Ogino, H. Promising biological therapies for ulcerative colitis: A review of the literature. World J. Gastrointest. Pathophysiol. 2015, 6, 219–227. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Takenaka, K.; Tominaga, K.; Kanazawa, M.; Fukushi, K.; Tanaka, T.; Kanamori, A.; Sugaya, T.; Tsuchida, K.; Iijima, M.; Goda, K.; et al. Endoscopic score vs. blood cell indices for determining timing of immunomodulator withdrawal in quiescent ulcerative colitis. Sci. Rep. 2019, 9, 17751. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sands, B.E.; Sandborn, W.J.; Panaccione, R.; O’Brien, C.D.; Zhang, H.; Johanns, J.; Adedokun, O.J.; Li, K.; Peyrin-Biroulet, L.; Van Assche, G.; et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N. Engl. J. Med. 2019, 381, 1201–1214. [Google Scholar] [CrossRef] [PubMed]
- Sandborn, W.J.; Feagan, B.G.; Marano, C.; Zhang, H.; Strauss, R.; Johanns, J.; Adedokun, O.J.; Guzzo, C.; Colombel, J.F.; Reinisch, W.; et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014, 146, 85–95. [Google Scholar] [CrossRef] [PubMed]
- Truelove, S.C.; Jewell, D.P. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974, 1, 1067–1070. [Google Scholar] [CrossRef]
- Matsuoka, K.; Kobayashi, T.; Ueno, F.; Matsui, T.; Hirai, F.; Inoue, N.; Kato, J.; Kobayashi, K.; Kobayashi, K.; Koganei, K.; et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. J. Gastroenterol. 2018, 53, 305–353. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schwartz, D.M.; Bonelli, M.; Gadina, M.; O’Shea, J.J. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat. Rev. Rheumatol. 2016, 12, 25–36. [Google Scholar] [CrossRef] [PubMed]
- Sandborn, W.J.; Ghosh, S.; Panes, J.; Vranic, I.; Su, C.; Rousell, S.; Niezychowski, W.; Study A3921063 Investigators. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N. Engl. J. Med. 2012, 367, 616–624. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sandborn, W.J.; Su, C.; Sands, B.E.; D’Haens, G.R.; Vermeire, S.; Schreiber, S.; Danese, S.; Feagan, B.G.; Reinisch, W.; Niezychowski, W.; et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N. Engl. J. Med. 2017, 376, 1723–1736. [Google Scholar] [CrossRef] [PubMed]
- Hart, A.L.; Ng, S.C. Review article: The optimal medical management of acute severe ulcerative colitis. Aliment. Pharmacol Ther. 2010, 32, 615–627. [Google Scholar] [CrossRef] [PubMed]
- Chen, H.C.; Ng, S.C. Emerging biologics in inflammatory bowel disease. J. Gastroenterol. 2017, 52, 141–150. [Google Scholar] [CrossRef] [PubMed]
- Winthrop, K.L.; Melmed, G.Y.; Vermeire, S.; Long, M.D.; Chan, G.; Pedersen, R.D.; Lawendy, N.; Thorpe, A.J.; Nduaka, C.I.; Su, C. Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm. Bowel Dis. 2018, 24, 2258–2265. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Motoya, S.; Watanabe, M.; Kim, H.J.; Kim, Y.H.; Han, D.S.; Yuasa, H.; Tabira, J.; Isogawa, N.; Arai, S.; Kawaguchi, I.; et al. Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: Subgroup analyses from three phase 3 multinational studies. Intest Res. 2018, 16, 233–245. [Google Scholar] [CrossRef] [PubMed]
AST | 15 U/L | WBC | 12.4 × 109/L |
ALT | 11 U/L | RBC | 3.92 × 1012/L |
ALP | 158 U/L | Hb | 12.2 g/dL |
γGTP | 15 U/L | Plt | 50.6 × 104/L |
T-Bil | 0.4 mg/dL | ESR (1 h) | 45 mm |
UN | 10 mg/dL | ||
Cre | 0.67 mg/dL | T-SPOT® | (-) |
TP | 7.3 mg/dL | HBsAg | (-) |
Alb | 3.5 mg/dL | HBcAb | (-) |
CRP | 3.8 mg/dL | CMV antigenemia | (-) |
Stool culture | Normal |
AST | 15 U/L | WBC | 11.3 × 109/L |
ALT | 19 U/L | Neutro | 72.2% |
ALP | 164 U/L | Lympho | 19.0% |
γGTP | 19 U/L | RBC | 3.49 × 1012/L |
T-Bil | 0.7 mg/dL | Hb | 11.1 g/dL |
UN | 7 mg/dL | Plt | 39.9 × 104/L |
Cre | 0.68 mg/dL | ESR (1 h) | 58 mm |
TP | 7.6 mg/dL | ||
Alb | 3.5 mg/dL | ||
CRP | 6.98 mg/dL |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tominaga, K.; Kanazawa, M.; Tanaka, T.; Kojimahara, S.; Sugaya, T.; Watanabe, S.; Yamamiya, A.; Majima, Y.; Iijima, M.; Goda, K.; et al. A Case of Lung Abscess Caused by Double Immunosuppressive Therapy to Treat Ulcerative Colitis. Medicina 2020, 56, 595. https://doi.org/10.3390/medicina56110595
Tominaga K, Kanazawa M, Tanaka T, Kojimahara S, Sugaya T, Watanabe S, Yamamiya A, Majima Y, Iijima M, Goda K, et al. A Case of Lung Abscess Caused by Double Immunosuppressive Therapy to Treat Ulcerative Colitis. Medicina. 2020; 56(11):595. https://doi.org/10.3390/medicina56110595
Chicago/Turabian StyleTominaga, Keiichi, Mimari Kanazawa, Takanao Tanaka, Shunsuke Kojimahara, Takeshi Sugaya, Shoko Watanabe, Akira Yamamiya, Yuichi Majima, Makoto Iijima, Kenichi Goda, and et al. 2020. "A Case of Lung Abscess Caused by Double Immunosuppressive Therapy to Treat Ulcerative Colitis" Medicina 56, no. 11: 595. https://doi.org/10.3390/medicina56110595
APA StyleTominaga, K., Kanazawa, M., Tanaka, T., Kojimahara, S., Sugaya, T., Watanabe, S., Yamamiya, A., Majima, Y., Iijima, M., Goda, K., & Irisawa, A. (2020). A Case of Lung Abscess Caused by Double Immunosuppressive Therapy to Treat Ulcerative Colitis. Medicina, 56(11), 595. https://doi.org/10.3390/medicina56110595